Mobile Menu Mobile Close

Search

LEARN MORE ABOUT OUR FEARLESS PURSUIT

LATEST NEWS

TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional composite (MSFC) score Data from the ULTIMATE I & II Phase 3 trials recently supported a BLA submission to the U.S.

Read More >

GET INVESTOR
INFORMATION

HEAR OUR
STORY

READ OUR
PUBLICATIONS

EXPLORE OUR
PIPELINE

JOIN OUR
TEAM

HEAR OUR
STORY

EXPLORE OUR
PIPELINE

READ OUR
PUBLICATIONS

JOIN OUR
TEAM

GET INVESTOR
INFORMATION

LATEST NEWS

TG Therapeutics Announces Data for Ublituximab in Multiple Sclerosis Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

New ULTIMATE I & II data presented at ECTRIMS shows ublituximab treatment is associated with significant improvement in the multiple sclerosis functional composite (MSFC) score Data from the ULTIMATE I & II Phase 3 trials recently supported a BLA submission to the U.S.

Read More >
logo

Email Us 1-877-575-TGTX (8489)

©2021 TG Therapeutics, Inc. All rights reserved.

You are now leaving TGTherapeutics.com, a website wholly owned and operated by TG Therapeutics, Inc. This link will take you to a website to which this Privacy Policy does not apply. TG Therapeutics, Inc., does not endorse or influence the content of websites that are not owned or operated by TG Therapeutics, Inc.

CONTINUE Return to tgtherapeutics.com